查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1836768

神经血管设备市场（按产品、适应症、技术、最终用户和分销管道）—2025-2032 年全球预测

Neurovascular Neurology Devices Market by Product, Indication, Technology, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，神经血管设备市场将成长 60 亿美元，复合年增长率为 8.02%。

主要市场统计数据
基准年2024年 32.3亿美元
预计2025年 35亿美元
预测年份：2032年 60亿美元
复合年增长率（%） 8.02%

神经血管设备的策略实施，重点在于临床紧迫性、多学科照护途径和影响结果的技术趋势

神经血管器械正处于技术创新、临床紧迫性和不断发展的护理路径的十字路口，需要医疗保健、投资和监管领域的相关人员清晰且基于临床的认知来采用。本介绍将重点介绍微创治疗和诊断影像的进步如何改变急性中风护理、动脉瘤管理和血管畸形治疗。临床医生越来越依赖兼具改进机械性能和更佳输送能力的精密器械，而影像解析度和程式引导系统的同步改进也推动了这一趋势。

临床情况是，脑血管意外的发病率和死亡率仍然很高，这给缩短治疗时间、提高手术成功率和改善长期神经系统预后带来了持续的压力。为此，设备开发人员专注于提高部署的可靠性、减少术中併发症，并创新材料科学以调节血栓形成和癒合反应。同时，卫生系统正在重组其网络，以优先考虑快速分流、集中血栓切除中心，并在适当的情况下扩大门诊手术的作用。

监管和报销动态仍然是采用轨蹟的核心，核准越来越依赖稳健的临床终点和对上市后监测的承诺。介入性神经放射科医生、神经外科医生和卒中神经科之间的合作正在加深，这种跨学科的合作正在加速设备的迭代改进和真实世界证据的生成。这些因素的共同作用，使得神经血管器械成为那些寻求对患者预后产生持久影响并创造长期价值的组织的策略重点。

设备工程、影像分析和护理服务重新设计如何重塑神经血管护理的临床采用、采购和创新途径

在仪器工程、数位诊断和医疗系统组织融合发展的推动下，神经血管介入领域正在经历变革性变革。在设备层面，从纯机械解决方案转向整合平台的转变正在加速。新型血流路径导流结构和生物活性表面处理技术反映出人们更加重视透过更少的辅助手术实现动脉瘤的持久闭塞，而回收器和抽吸器设计的创新则优先考虑血栓截留和减少内皮损伤。同时，增强的成像和分析技术能够更精确地表征病变并进行手术规划，从而支援针对特定解剖和病理亚型的设备迭代。

在营运方面，我们看到了明显的转变，即将某些程序分散到低危诊中心，在这些中心，病人选择和精简的方案能够实现安全且经济高效的干预。这种混合医疗模式的实现得益于针对门诊使用而最佳化的设备设计和简化的库存管理。此外，临床试验设计也不断发展，强调自适应方案和真实世界证据，从而能够在保持方法学严谨性的同时，更快地实用化有前景的技术。

在宏观面，供应链韧性和监管协调正在影响产品蓝图和打入市场策略。企业正在投资本地製造、战略伙伴关係和基本契约，以应对报销压力和采购合理化。这些转型并非渐进式的；它们将重塑竞争定位、临床医生的决策以及广泛临床应用的时间表。

评估美国新关税对整个设备组合的采购、製造转移和创新资金的累积营运和策略影响

2025年美国加征关税为参与全球神经血管器械生产和分销的相关人员带来了新的复杂性，其累积影响涵盖采购、製造和研发投资决策。关税带来的成本压力在跨境供应链中集中的零件和原材料上最为明显，例如特殊合金、导管轴和渗透性标记物。随着这些投入成本的上涨，製造商面临策略性选择：吸收成本、重新分配利润，还是将其转嫁给下游经销商和医疗保健系统。

因此，采购组织和医院系统正在加快努力，实现供应商多元化，审查合约条款，并透过长期合约和在地采购安排确保价格的可预测性。对于医疗设备製造商而言，关税将促使他们重组供应链，可能采取近岸生产、筛选合格的替代供应商以及尽可能加强垂直整合等措施。虽然这些应对措施可以减轻长期风险，但通常需要前期投资和延长的资格认定期，这会与研发资金产生竞争。

规模较小的创新企业尤其容易受到影响，因为不断上涨的进口成本可能会限制它们在没有策略联盟的情况下扩大临床试验和商业化上市的能力。同时，拥有多元化製造地的大型现有企业可以利用其规模来规范价格波动，补偿这样做会减少原本可以用于产品开发和上市的资源。总体而言，关税是重新评估国际产品系列的关税补贴（CTC）的催化剂，并强调了韧性规划、情境建模以及与付款方主动对话的重要性，以维护临床医生和患者的可及性。

将产品设计、临床指征、交付技术、护理环境和分销策略联繫起来的细分级洞察，以推动采用和差异化

細項分析揭示了临床需求、设备力学和通路动态如何相互作用以形成采用模式和商业性优先顺序。依产品类型，球囊血管成形术导管透过顺应性和非顺应性球囊技术进行区分。顺应性球囊适用于精细的血管重塑，而当需要精确的管腔扩张时，非顺应性球囊是首选。栓塞线圈有多种类型，包括裸线圈、涂层线圈和水凝胶线圈。每种亚型都在即时闭塞、组织整合和长期稳定性之间进行权衡，帮助临床医生选择合适的线圈。可生物降解的流量转向器对于寻求血管修復而又不想承受终生植入负担的临床医生很有吸引力，而永久性流量转向器仍然是某些复杂动脉瘤形态的预设选择。神经血管支架製造为球囊扩张型或自扩张式，选择取决于对径向力、血管迷宫性和输送限制的需求。血栓摘取支架系统（例如 Solitaire 和 Trevo 设计）因其血块接合机制、输送特性以及与吸痰辅助设备的兼容性而有所不同。

依适应症分析，动脉瘤封堵策略必须考虑动脉瘤的解剖结构与囊状结构，而器械的选择则受瘤颈形态和载瘤血管受累情况的影响。动静脉畸形的治疗需要不同的手术方法，着重于血管巢的建立和栓塞控制，而出血性中风的治疗则优先考虑稳定止血和预防再出血。缺血性中风的治疗分为前循环中风和后循环中风，解剖入路、侧支循环和时间敏感性决定了器械的选择和手术策略。

技术细分区分为化学血栓溶解、血流改道疗法和机械血栓切除术。机械血栓切除术进一步细分为抽吸导管策略和血栓摘取支架，每种策略在血栓移除效率和与辅助器具的兼容性方面均具有互补优势。最终使用者细分分为门诊手术中心、医院和专科诊所。门诊环境需要针对高效週转和不太复杂的病例进行优化的设备，而医院则维持大量库存以用于紧急手术，专科诊所优先考虑支持可重复手术和专门后续护理的设备。直销和分销商之间分销管道的动态影响培训、服务水准和定价透明度，直销能够提供更紧密的临床支持，而分销商提供更广泛的地理覆盖和库存缓衝。总之，这些细分揭示了产品设计、临床指征、技术选择、医疗环境和通路策略必须如何协调才能实现临床影响和商业性成功。

美洲、欧洲、中东和非洲地区以及亚太地区的区域动态和临床基础设施差异将影响监管途径、报销优先顺序和实施模式

区域动态反映了监管、提供者基础设施和付款人行为的差异，正在塑造整个神经血管器械领域的临床实践和商业策略。在美洲，强大的中风护理系统和整合的医院网路支援先进的血栓切除术和血流分流技术的快速应用。卓越的医疗中心和高手术量使得强化训练计画成为可能，并促进了真实世界证据的收集，从而进一步加速了器械的采用。该地区的采购环境通常强调捆绑式医疗经济学和价值展示，鼓励器材申办方将临床数据与健康经济学叙述结合。

欧洲、中东和非洲由于各国监管途径、报销政策差异以及介入科医生取得途径的差异，呈现出差异性。在西欧，集中式卫生技术评估流程和强大的临床註册系统创造了优先考虑长期疗效和成本效益的采取路径。中东和非洲部分地区已开始投资提升神经介入能力，但劳动力分布和基础设施的差异限制了其采用，从而为可扩展的培训和服务模式提供了有针对性的机会。

亚太地区拥有广阔而多样化的机会，其特点是医院快速扩张、三级卒中中心投资不断增加以及本地製造业蓬勃发展。不同司法管辖区的监管时间表差异巨大，打入市场策略通常需要与区域经销商和本地製造商合作。此外，人口结构趋势和对卒中风险因素的日益关注正在推动对急性护理设备和慢性病管理解决方案的需求，而某些市场的价格敏感性则需要定制产品系列和灵活的分销模式。在所有地区，协调临床证据产生和上市后监测实践对于维持设备应用和持续改进仍然至关重要。

结合临床证据、培训计划和供应链弹性的竞争定位和伙伴关係策略确保了干预专家的持久偏好

神经血管器械领域的竞争动态取决于规模主导能力与敏捷创新之间的平衡。大型医疗科技公司凭藉其广泛的临床试验网络、丰富的监管经验以及一体化的服务产品，与大型机构保持持久的合作关係。为了赢得临床偏好并向付款人展示其价值，这些新兴企业正在推进差异化技术，例如新型生物可吸收血流转向器、先进的聚合物涂层弹簧圈以及下一代抽吸导管。如果有令人信服的临床数据支持，这些技术可以迅速引起临床关注。

伙伴关係和策略联盟正变得越来越普遍，这使得规模较小的创新者能够获得商业化的专业知识和规模，同时大型公司也能够利用有针对性的能力来扩充其产品线。併购仍然是获取新智慧财产权和扩大地域覆盖范围的重要机制，但监管的复杂性以及整合临床教育工作的需求意味着交易必须经过仔细审查。

提供现场监考、混合模拟程序和术后分析的公司能够提高临床医生的采用率，并缩短复杂设备的学习曲线。最后，积极关注供应链弹性、成本透明度和价值展示的公司，将为医疗系统克服预算和采购限制提供有利条件。这些策略行动共同创造了一个竞争环境，其中临床证据、支持性基础设施和供应链可靠性与设备性能同等重要。

为领导者提供一系列实用且具高影响力的建议，以协调临床证据、供应链弹性、商业化模式和付款人参与，以实现持久成长

产业领导者应采取多管齐下的策略，将产品创新与商业严谨性、临床参与度和供应链韧性结合。首先，优先考虑能够产生有意义的以患者为中心的终点和可操作证据，并引起临床医生和付款人共鸣的临床项目。其次，透过重新设计供应链策略、寻找替代供应商、考虑关键零件的近岸外包以及建立维持上市计画的库存缓衝，来降低关税和零件集中度风险。

第三，我们将根据当地情况调整商业模式，将高销售量中心的直销与在覆盖率和本地关係至关重要的市场与经销商合作结合。第四，我们将投资临床医生培训基础设施，包括模拟、监考和数位决策支援，以缩短采用曲线并减少程序差异。第五，我们将儘早与付款人沟通，提供全面的价值檔案，清楚阐明临床结果和健康经济影响。

最后，整合数位化工具，增强手术规划、后续跟进和设备性能监控，建构差异化服务层，从而支援高端定位。透过执行这些相互关联的优先事项，产业领导者可以加速安全应用，应对成本压力，并持续投资于下一代技术。

一种透明的混合方法研究途径，结合临床医生访谈、专家小组和系统文献综合来检验临床和商业性见解

基础调查方法结合了严谨的一级研究和二级研究，以确保研究的相关性、有效性和对相关人员的实用性。一级研究包括对介入专家、医院采购负责人和设备管理人员进行结构化访谈，以了解他们在设备选择、操作偏好和应用障碍方面的现场观点。此外，由中风和血管神经外科专家组成的专家专题研讨会对这些访谈进行了补充，以检验临床假设并解读操作趋势。二级研究则包括对同行评审出版物、临床试验註册中心、监管文件和设备技术文献进行系统性回顾，以对研究结果进行三角检验并揭示技术创新的轨迹。

数据合成透过将定性见解与客观指标（例如器械核准历史记录、指南更新和已发表的程序结果）进行交叉验证来实现。在适当情况下，进行了情境分析，以评估对政策变化和供应链中断的敏感度。品管流程包括独立编辑评审、临床顾问检验以及概述纳入标准、访谈方案和限制的调查方法检验。假设和证据来源的透明度支持了所提出见解的可信度，同时也认识到临床实践和政策环境正在不断发展，需要持续监测。

简洁的综合强调了技术创新、证据产生和商业性实施之间的基本一致性，以将设备进步转化为改善的患者结果。

总而言之，神经血管神经病学器械领域的特点是技术快速进步、医疗服务模式不断发展，以及对供应链价值和韧性的日益重视。器材设计和影像处理的进步显着提高了操作能力，但其永续应用取决于可靠的临床证据、审慎的报销策略以及整个医疗系统的营运准备。政策变革和贸易动态带来了新的限制因素，需要透过多元化采购和策略伙伴关係关係来积极应对。

未来的成功将青睐那些将临床创新与严谨的商业化相结合、投资于临床医生培训和上市后证据、并采取尊重监管和支付方差异的灵活区域战略的机构。将产品开发与可证明的疗效和服务导向的主张提案结合，将使相关人员能够应对定义该市场的临床需求、经济压力和技术机会之间的复杂相互作用。持续关注真实世界的性能数据并与临床医生群体合作，对于将设备创新转化为大规模改善的患者疗效至关重要。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 机器人血栓切除系统与即时影像引导结合，实现精准血栓切除
  • 生物可吸收支架的出现旨在减少长期血管刺激并改善患者预后
  • 开发基于人工智慧的诊断平台，用于早期发现高风险患者的脑血管异常
  • 导管设计取得进展，采用亲水涂层和灵活的远端尖端，用于复杂的神经血管导航
  • 扩展远距神经介入服务，以便在血管内手术期间实现远距指导和咨询

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第 8 章神经血管设备市场（按产品）

  • 球囊血管成形术导管
    • 顺应性球囊
    • 不合规球囊
  • 栓塞线圈
    • 裸露线圈
    • 涂层卷材
    • 水凝胶线圈
  • 流量转向器
    • 可生物降解的导流器
    • 永久流量转向器
  • 神经血管支架
    • 球囊扩张型支架
    • 自动扩张型支架
  • 血栓摘取支架系统
    • 纸牌
    • 特雷沃

第九章神经血管设备市场（按适应症）

  • 动脉瘤闭塞
    • 梭形动脉瘤
    • 囊状动脉瘤
  • 动静脉畸形
  • 出血性中风
  • 缺血性中风
    • 前循环卒中
    • 后循环中风

第 10 章神经血管设备市场（按技术）

  • 化学溶栓
  • 流量转换
  • 机械血栓切除术
    • 吸痰导管
    • 支架取栓器

第 11 章神经血管设备市场（依最终用户）

  • 门诊手术中心
  • 医院
  • 专科诊所

第 12 章神经血管设备市场（依通路）

  • 直销
  • 经销商

第 13 章。神经血管设备市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 14 章神经血管设备市场（按类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章。按国家/地区分類的神经血管设备市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Medtronic plc
    • Stryker Corporation
    • Johnson & Johnson
    • Penumbra, Inc.
    • Terumo Corporation
    • MicroPort Scientific Corporation
    • Boston Scientific Corporation
    • MicroVention, Inc.
    • Cerenovus, LLC
    • Acandis GmbH
Product Code: MRR-036C5CF3B4E4

The Neurovascular Neurology Devices Market is projected to grow by USD 6.00 billion at a CAGR of 8.02% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.23 billion
Estimated Year [2025] USD 3.50 billion
Forecast Year [2032] USD 6.00 billion
CAGR (%) 8.02%

A strategic introduction to neurovascular devices emphasizing clinical urgency, multidisciplinary care pathways, and technological trends shaping procedural outcomes

Neurovascular neurology devices are at the intersection of technological innovation, clinical urgency, and evolving care pathways, demanding a clear, clinically informed introduction for stakeholders across healthcare, investment, and regulatory spheres. This introduction frames the current landscape by highlighting how advances in minimally invasive therapies and imaging have reshaped acute stroke care, aneurysm management, and the treatment of vascular malformations. Clinicians increasingly rely on precision devices that integrate refined mechanical properties with improved deliverability, and this trend is supported by parallel enhancements in imaging resolution and procedural guidance systems.

The clinical context is defined by persistently high morbidity and mortality associated with cerebrovascular events, which creates sustained pressure to improve time-to-treatment, procedural success rates, and long-term neurological outcomes. In response, device developers have focused on reliability of deployment, reduced intraprocedural complications, and materials science innovations that modulate thrombogenicity and healing responses. At the same time, health systems are realigning care networks to prioritize rapid triage, centralized thrombectomy-capable centers, and expanded roles for ambulatory procedural settings where appropriate.

Regulatory and reimbursement dynamics remain central to adoption trajectories, with approvals increasingly tied to robust clinical endpoints and post-market surveillance commitments. Collaboration among interventional neuroradiologists, neurosurgeons, and stroke neurologists is deepening, and this multidisciplinary engagement is accelerating iterative device improvements and real-world evidence generation. Taken together, these forces situate neurovascular devices as a strategic priority for organizations seeking durable impact on patient outcomes and long-term value creation.

How device engineering, imaging analytics, and care delivery redesign are together reshaping clinical adoption, procurement, and innovation pathways in neurovascular care

The landscape of neurovascular interventions is undergoing transformative shifts driven by convergent advances in device engineering, digital diagnostics, and health-system organization. At the device level, a move from purely mechanical solutions toward integrated platforms has accelerated: newer flow diversion constructs and bioactive surface treatments reflect an emphasis on durable aneurysm occlusion with fewer adjunctive procedures, while innovations in retriever and aspiration designs prioritize clot engagement and reduced endothelial trauma. Concurrently, imaging and analytics enhancements are enabling more accurate lesion characterization and procedural planning, which in turn supports device iteration that targets specific anatomical and pathological subtypes.

Operationally, there is an unmistakable shift toward decentralizing certain procedures to low-acuity settings where patient selection and streamlined protocols permit safe, cost-efficient interventions. This hybridization of care delivery models is being enabled by device designs optimized for outpatient use and simplified inventory management. In addition, clinical trial designs are evolving to emphasize adaptive protocols and real-world evidence, allowing faster translation of promising technologies while preserving methodological rigor.

On the macro front, supply chain resilience and regulatory harmonization are influencing product roadmaps and market entry strategies. Companies are investing in localized manufacturing, strategic partnerships, and value-based contracting to navigate reimbursement pressures and procurement rationalization. Taken together, these transformative shifts are not incremental; they reshape competitive positioning, clinician decision-making, and the timelines for broad clinical adoption.

Evaluating the cumulative operational and strategic consequences of new U.S. tariffs on procurement, manufacturing relocation, and innovation funding across device portfolios

The imposition of United States tariffs in 2025 has introduced a new layer of complexity for stakeholders engaged in the global production and distribution of neurovascular devices, with cumulative effects that extend across procurement, manufacturing, and R&D investment decisions. Tariff-driven cost pressure is most immediately apparent in components and raw materials that are concentrated in cross-border supply chains, including specialty alloys, catheter shafts, and radio-opaque markers. When these inputs become more expensive, manufacturers face strategic choices about absorbing costs, reallocating margins, or passing increases downstream to distributors and health systems.

Consequently, procurement organizations and hospital systems are reassessing supplier diversification and contract terms, accelerating efforts to secure price predictability through longer-term agreements or local sourcing arrangements. For device companies, the tariffs incentivize supply chain reconfiguration: nearshoring production, qualifying alternate suppliers, and increasing vertical integration where feasible. These responses can mitigate exposure over time but often require upfront capital and extended qualification timelines that compete with R&D allocations.

Smaller innovators are particularly vulnerable, as elevated import costs may constrain their ability to scale clinical trials and commercial launches without strategic partnerships. At the same time, larger incumbents with diversified manufacturing footprints can leverage scale to normalize pricing changes, albeit at the cost of redirecting resources that might otherwise fund product development or market expansion. In aggregate, the tariffs catalyze a re-evaluation of the cost-to-serve for international product portfolios, reinforcing the importance of resilience planning, scenario modeling, and proactive dialogue with payers to preserve access for clinicians and patients.

Segment-level insights connecting product design, clinical indications, delivery technologies, care settings, and distribution strategies to drive adoption and differentiation

A nuanced segmentation analysis reveals how clinical need, device mechanics, and channel dynamics interact to shape adoption patterns and commercial priorities. Within product categories, balloon angioplasty catheters are differentiated by compliant versus noncompliant balloon technologies, where compliant balloons are preferred for delicate vessel remodeling and noncompliant variants are favored when precise luminal expansion is required. Embolic coils vary across bare coils, coated coils, and hydrogel coils, and each subtype presents trade-offs between immediate occlusion, tissue integration, and long-term stability that inform clinician selection. Flow diverters divide into biodegradable and permanent devices; biodegradable flow diverters appeal to clinicians seeking vessel restoration without lifelong implant burden, while permanent flow diverters remain the default for certain complex aneurysm morphologies. Neurovascular stents are produced as balloon-expandable or self-expanding constructs, with choice contingent on radial force needs, vessel tortuosity, and delivery constraints. Stent retriever systems, exemplified by Solitaire and Trevo designs, are distinguished by clot engagement mechanics, deliverability profiles, and compatibility with aspiration adjuncts.

When analyzed by indication, aneurysm occlusion strategies must account for fusiform versus saccular anatomy, with device selection influenced by neck morphology and parent vessel involvement. Treatments for arteriovenous malformations require a different procedural mindset focused on nidus access and embolic control, while hemorrhagic stroke interventions prioritize hemostatic stabilization and prevention of rebleeding. Ischemic stroke management bifurcates into anterior circulation and posterior circulation strokes, where anatomical access, collateral circulation, and time sensitivity dictate device choice and procedural strategy.

Technological segmentation highlights distinctions between chemical thrombolysis, flow diversion, and mechanical thrombectomy. Mechanical thrombectomy further subdivides into aspiration catheter strategies and stent retrievers, each offering complementary strengths in clot retrieval efficiency and compatibility with adjunctive devices. End user segmentation shows divergent needs among ambulatory surgical centers, hospitals, and specialty clinics: ambulatory settings require devices optimized for streamlined turnover and lower complexity cases, hospitals maintain broad inventories for high-acuity procedures, and specialty clinics emphasize devices that support repeatable interventions and specialized follow-up care. Distribution channel dynamics between direct sales and distributors influence training, service levels, and pricing transparency, with direct sales enabling tighter clinical support and distributors offering broader geographic reach and inventory buffering. Collectively, these segmentation lenses illuminate how product design, clinical indication, technology choice, care setting, and channel strategy must be aligned to realize both clinical impact and commercial success.

Regional dynamics and clinical infrastructure differences that influence regulatory pathways, reimbursement priorities, and adoption models across Americas, EMEA, and Asia-Pacific

Regional dynamics shape both clinical practice and commercial strategy across the neurovascular device landscape, reflecting differences in regulation, provider infrastructure, and payer behavior. In the Americas, robust stroke systems of care and consolidated hospital networks support rapid adoption of advanced thrombectomy and flow diversion technologies; centers of excellence and high procedural volumes enable intensive training programs and foster real-world evidence collection that further accelerates device uptake. The purchasing environment in this region often emphasizes bundled care economics and value demonstration, prompting device sponsors to couple clinical data with health-economic narratives.

Europe, the Middle East & Africa exhibits heterogeneity driven by national regulatory pathways, variable reimbursement policies, and disparate access to interventionists. In Western Europe, centralized health technology assessment processes and strong clinical registries create a pathway for adoption that prioritizes long-term outcomes and cost-effectiveness. In parts of the Middle East and Africa, investment in neurointerventional capacity is emerging, but adoption is constrained by workforce distribution and infrastructure gaps, leading to targeted opportunities for scalable training and service models.

Asia-Pacific presents a large and diverse opportunity set characterized by rapid hospital expansion, increased investment in tertiary stroke centers, and local manufacturing growth. Regulatory timelines vary significantly across jurisdictions, and market entry strategies often require partnerships with regional distributors or local manufacturers. Furthermore, demographic trends and growing awareness of stroke risk factors are driving demand for both acute intervention devices and chronic management solutions, while price sensitivity in certain markets compels tailored product portfolios and flexible commercial arrangements. Across all regions, harmonizing clinical evidence generation and post-market surveillance practices remains critical to sustaining adoption and informing iterative device improvements.

Competitive positioning and partnership strategies that combine clinical evidence, training programs, and supply chain resilience to secure lasting preference among interventionists

Competitive dynamics across the neurovascular devices arena are defined by a balance between scale-driven capabilities and nimble innovation. Leading medtech firms leverage extensive clinical trial networks, broad regulatory experience, and integrated service offerings to maintain durable relationships with high-volume centers. These incumbents often invest in complementary technologies, training academies, and long-term post-market studies to entrench clinical preference and demonstrate value to payers. At the same time, agile emerging companies are advancing differentiated technologies-such as novel bioresorbable flow diverters, advanced polymer-coated coils, and next-generation aspiration catheters-that can rapidly capture clinical interest when supported by compelling procedural data.

Partnerships and strategic alliances are increasingly common, enabling smaller innovators to access commercialization expertise and scale while allowing larger firms to augment their pipelines with targeted capabilities. Mergers and acquisitions continue to be a key mechanism for acquiring novel intellectual property and expanding geographic reach, although transactions are subject to careful scrutiny given regulatory complexity and the need to integrate clinical education efforts.

Service and training models are also a point of differentiation; companies that provide hands-on proctoring, hybrid simulation programs, and post-procedural analytics strengthen clinician adoption and reduce the learning curve for complex devices. Finally, companies that proactively address supply chain resilience, cost transparency, and value demonstration position themselves favorably with health systems navigating budgetary and procurement constraints. Collectively, these strategic behaviors define a competitive environment where clinical evidence, support infrastructure, and supply-chain reliability are as consequential as device performance.

A pragmatic set of high-impact recommendations for leaders to align clinical evidence, supply chain resilience, commercialization models, and payer engagement for durable growth

Industry leaders should adopt a multi-pronged strategy that aligns product innovation with commercialization rigor, clinical engagement, and supply chain resilience. First, prioritize clinical programs that generate meaningful, patient-centric endpoints and pragmatic evidence that resonates with clinicians and payers; registries and pragmatic trials can complement randomized studies and facilitate faster, generalizable insights. Second, redesign supply chain strategies to mitigate tariff exposure and component concentration risks by qualifying alternate suppliers, considering nearshoring for critical components, and establishing inventory buffers that preserve launch timelines.

Third, tailor commercial models to regional contexts by combining direct sales in high-volume centers with distributor partnerships in markets where breadth of coverage and local relationships are paramount. Fourth, invest in clinician training infrastructures that include simulation, proctoring, and digital decision support to shorten adoption curves and reduce procedural variability. Fifth, engage payers early with comprehensive value dossiers that articulate both clinical outcomes and health economic impact; performance-based contracting and outcome guarantees can be considered where alignment is feasible.

Finally, embed digital tools that enhance procedural planning, follow-up, and device performance monitoring to create a differentiated service layer that supports premium positioning. By executing on these interconnected priorities, industry leaders can accelerate safe adoption, manage cost pressures, and sustain investment in next-generation technologies.

A transparent mixed-methods research approach combining clinician interviews, expert panels, and systematic literature synthesis to validate clinical and commercial insights

The underlying research methodology combines rigorous primary and secondary approaches to ensure validity, relevance, and practical utility for stakeholders. Primary research included structured interviews with interventionalists, hospital procurement leaders, and device executives to capture frontline perspectives on device selection, procedural preferences, and adoption barriers. These interviews were complemented by expert panel discussions with clinicians specializing in stroke and vascular neurosurgery to validate clinical assumptions and interpret procedural trends. Secondary research involved systematic review of peer-reviewed publications, clinical trial registries, regulatory filings, and technical device literature to triangulate findings and contextualize innovation trajectories.

Data synthesis relied on cross-validation of qualitative insights with objective indicators such as device approval histories, guideline updates, and published procedural outcomes. Where appropriate, scenario analysis was applied to assess sensitivity to policy changes and supply chain disruptions. Quality control processes included independent editorial review, clinical advisor validation, and methodological documentation that outlines inclusion criteria, interview protocols, and limitations. Transparency about assumptions and the sources of evidence underpins the confidence in the insights presented, while acknowledging that clinical practice and policy environments continue to evolve and warrant ongoing monitoring.

A concise synthesis emphasizing the imperative to align innovation, evidence generation, and commercial execution to translate device advances into improved patient outcomes

In conclusion, the neurovascular neurology device environment is characterized by rapid technological progress, evolving care delivery models, and intensified attention to value and resilience in supply chains. Advances in device design and imaging have materially improved procedural capabilities, but sustainable adoption depends on robust clinical evidence, sensible reimbursement strategies, and operational readiness across healthcare systems. Policy shifts and trade dynamics have introduced new constraints that require proactive mitigation through diversified sourcing and strategic partnerships.

Future success will favor organizations that integrate clinical innovation with disciplined commercialization, invest in clinician training and post-market evidence, and adopt flexible regional strategies that respect regulatory and payer heterogeneity. By aligning product development with demonstrable outcomes and service-oriented propositions, stakeholders can better navigate the complex interplay of clinical need, economic pressures, and technological opportunity that defines this market. Continued attention to real-world performance data and collaborative engagement with the clinician community will be crucial to translating device innovation into improved patient outcomes at scale.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of robot-assisted thrombectomy systems with real-time imaging guidance for precise clot retrieval
  • 5.2. Emergence of bioresorbable stents designed to reduce long-term vessel irritation and improve patient outcomes
  • 5.3. Development of AI-powered diagnostic platforms for early detection of cerebrovascular anomalies in high-risk patients
  • 5.4. Advancements in catheter design featuring hydrophilic coatings and distal-tip flexibility for complex neurovascular navigation
  • 5.5. Expansion of tele-neurointervention services enabling remote guidance and consultation during endovascular procedures

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neurovascular Neurology Devices Market, by Product

  • 8.1. Balloon Angioplasty Catheters
    • 8.1.1. Compliant Balloons
    • 8.1.2. Noncompliant Balloons
  • 8.2. Embolic Coils
    • 8.2.1. Bare Coils
    • 8.2.2. Coated Coils
    • 8.2.3. Hydrogel Coils
  • 8.3. Flow Diverters
    • 8.3.1. Biodegradable Flow Diverters
    • 8.3.2. Permanent Flow Diverters
  • 8.4. Neurovascular Stents
    • 8.4.1. Balloon-Expandable Stents
    • 8.4.2. Self-Expanding Stents
  • 8.5. Stent Retriever Systems
    • 8.5.1. Solitaire
    • 8.5.2. Trevo

9. Neurovascular Neurology Devices Market, by Indication

  • 9.1. Aneurysm Occlusion
    • 9.1.1. Fusiform Aneurysm
    • 9.1.2. Saccular Aneurysm
  • 9.2. Arteriovenous Malformations
  • 9.3. Hemorrhagic Stroke
  • 9.4. Ischemic Stroke
    • 9.4.1. Anterior Circulation Stroke
    • 9.4.2. Posterior Circulation Stroke

10. Neurovascular Neurology Devices Market, by Technology

  • 10.1. Chemical Thrombolysis
  • 10.2. Flow Diversion
  • 10.3. Mechanical Thrombectomy
    • 10.3.1. Aspiration Catheters
    • 10.3.2. Stent Retrievers

11. Neurovascular Neurology Devices Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Neurovascular Neurology Devices Market, by Distribution Channel

  • 12.1. Direct Sales
  • 12.2. Distributors

13. Neurovascular Neurology Devices Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Neurovascular Neurology Devices Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Neurovascular Neurology Devices Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Medtronic plc
    • 16.3.2. Stryker Corporation
    • 16.3.3. Johnson & Johnson
    • 16.3.4. Penumbra, Inc.
    • 16.3.5. Terumo Corporation
    • 16.3.6. MicroPort Scientific Corporation
    • 16.3.7. Boston Scientific Corporation
    • 16.3.8. MicroVention, Inc.
    • 16.3.9. Cerenovus, LLC
    • 16.3.10. Acandis GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NEUROVASCULAR NEUROLOGY DEVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. NEUROVASCULAR NEUROLOGY DEVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NEUROVASCULAR NEUROLOGY DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COMPLIANT BALLOONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COMPLIANT BALLOONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COMPLIANT BALLOONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COMPLIANT BALLOONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COMPLIANT BALLOONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COMPLIANT BALLOONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NONCOMPLIANT BALLOONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NONCOMPLIANT BALLOONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NONCOMPLIANT BALLOONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NONCOMPLIANT BALLOONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NONCOMPLIANT BALLOONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NONCOMPLIANT BALLOONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BARE COILS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BARE COILS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BARE COILS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BARE COILS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BARE COILS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BARE COILS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COATED COILS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COATED COILS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COATED COILS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COATED COILS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COATED COILS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COATED COILS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HYDROGEL COILS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HYDROGEL COILS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HYDROGEL COILS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HYDROGEL COILS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HYDROGEL COILS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HYDROGEL COILS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BIODEGRADABLE FLOW DIVERTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BIODEGRADABLE FLOW DIVERTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BIODEGRADABLE FLOW DIVERTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BIODEGRADABLE FLOW DIVERTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BIODEGRADABLE FLOW DIVERTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BIODEGRADABLE FLOW DIVERTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PERMANENT FLOW DIVERTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PERMANENT FLOW DIVERTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PERMANENT FLOW DIVERTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PERMANENT FLOW DIVERTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PERMANENT FLOW DIVERTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PERMANENT FLOW DIVERTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SELF-EXPANDING STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SELF-EXPANDING STENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SELF-EXPANDING STENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SELF-EXPANDING STENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SELF-EXPANDING STENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SELF-EXPANDING STENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SOLITAIRE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SOLITAIRE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SOLITAIRE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SOLITAIRE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SOLITAIRE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SOLITAIRE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TREVO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TREVO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TREVO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TREVO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TREVO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TREVO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FUSIFORM ANEURYSM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FUSIFORM ANEURYSM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FUSIFORM ANEURYSM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FUSIFORM ANEURYSM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FUSIFORM ANEURYSM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FUSIFORM ANEURYSM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SACCULAR ANEURYSM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SACCULAR ANEURYSM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SACCULAR ANEURYSM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SACCULAR ANEURYSM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SACCULAR ANEURYSM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SACCULAR ANEURYSM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HEMORRHAGIC STROKE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HEMORRHAGIC STROKE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HEMORRHAGIC STROKE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HEMORRHAGIC STROKE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HEMORRHAGIC STROKE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HEMORRHAGIC STROKE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANTERIOR CIRCULATION STROKE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANTERIOR CIRCULATION STROKE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANTERIOR CIRCULATION STROKE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANTERIOR CIRCULATION STROKE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANTERIOR CIRCULATION STROKE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANTERIOR CIRCULATION STROKE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY POSTERIOR CIRCULATION STROKE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY POSTERIOR CIRCULATION STROKE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY POSTERIOR CIRCULATION STROKE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY POSTERIOR CIRCULATION STROKE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY POSTERIOR CIRCULATION STROKE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY POSTERIOR CIRCULATION STROKE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY CHEMICAL THROMBOLYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY CHEMICAL THROMBOLYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY CHEMICAL THROMBOLYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY CHEMICAL THROMBOLYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY CHEMICAL THROMBOLYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY CHEMICAL THROMBOLYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ASPIRATION CATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ASPIRATION CATHETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ASPIRATION CATHETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ASPIRATION CATHETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ASPIRATION CATHETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ASPIRATION CATHETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 280. NO